Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus. SVV-001 is already in Phase I/II and has a clinical safety record in humans. SVV-001 binds to the TEM8 receptor which is common in many solid tumors like breast cancer, lung cancer and neuroendocrine tumors. SVV-001 is also being considered as a viral vector for gene therapy targeting the TEM8 receptor in solid tumors.
Company Details
- Employees
- 9
- Address
- Philadelphia, Pa 19103, Us
- Phone
- 484-883-9725
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- senecatherapeutics.com
- HQ
- Philadelphia, PA
Seneca Therapeutics, Inc. Questions
Seneca Therapeutics, Inc.'s helpline number is 484-883-9725
Seneca Therapeutics, Inc.'s website is senecatherapeutics.com
Seneca Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/seneca-therapeutics-inc
Seneca Therapeutics, Inc. has
9 employees.
View email and phone details for 9
employees at Seneca Therapeutics, Inc..
Seneca Therapeutics, Inc.'s industry is
Biotechnology Research
Seneca Therapeutics, Inc.'s top competitors are
Verismo Therapeutics,
Legend Biotech,
Iecure, Inc.,
Temple Therapeutics,
Larimar Therapeutics Inc.,
Vertex Biopharm Consulting,
Vyriad,
Adaptimmune,
Sfa Therapeutics,
Indigo Biosciences, Inc.
Seneca Therapeutics, Inc.'s categories are Biotechnology Research
